Brevan Howard Capital Management LP Cullinan Oncology, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 45,936 shares of CGEM stock, worth $392,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,936
Previous 19,227
138.91%
Holding current value
$392,752
Previous $144,000
88.89%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CGEM
# of Institutions
149Shares Held
65.1MCall Options Held
10.7KPut Options Held
14.4K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.4 Million8.21% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.77MShares$49.3 Million6.64% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.2 Million1.84% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.2 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $390M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...